autologous hematopoietic cells transduced with a lentiviral vector with dclre1c
Cell therapyexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2018 (NCT03538899)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- leukocytesSupplementation
leukocytes supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05071222 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2021 | APHP - Hôpital Necker, Assistance Publique - Hôpitaux de Paris, Imagine Institute |
| NCT03538899 | Phase 1/Phase 2 (Phase 2) | May 31, 2018 | University of California, San Francisco |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| APHP - Hôpital Necker | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Imagine Institute | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2018 |
4 organizations
Page 1 / 1